Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (DE:F6T)
BERLIN:F6T
Fate Therapeutics (F6T) Stock Price & Analysis
0 Followers
F6T Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.58 - €7.59
Previous Close€3.61
Volume0.00
Average Volume (3M)376.00
Market Cap
€404.11M
Enterprise Value€206.46M
Total Cash (Recent Filing)$315.18M
Total Debt (Recent Filing)$103.54M
Price to Earnings (P/E)N/A
Beta1.07
Next Earnings
May 01, 2024EPS Estimate
-€0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding99,237,508
10 Day Avg. Volume0
30 Day Avg. Volume376
Standard Deviation0.29
R-Squared0.05
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)1.02
Price to Sales (P/S)65.60
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.25
Enterprise Value/Gross Profit3.25
Enterprise Value/Ebitda-1.34
Forecast
1Y Price Target
€6.78Price Target Upside87.73% Upside
Rating ConsensusHold
Number of Analyst Covering15
Fate Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentFate Therapeutics is advancing a Phase 1 study of FT819 in systemic lupus erythematosus with translational data expected.
Financial HealthFate ended the year with roughly $316.2M in cash, which should provide an operational runway into the second half of 2025.
Upcoming MilestonesInitial data from studies on FT819 and FT522 expected in the second half of the year could be key catalysts for the company.
Bears Say
Clinical ValidationFATE’s induced pluripotent stem cell (iPSC) platform has yet to be clinically validated, especially on the manufacturing front.
Market CompetitionThe market for CD19 CAR-T therapies is saturated with multiple companies at similar stages of development, taking a conservative view on FATE's FT819.
Product DevelopmentThe pace of data release for FATE's oncology focus was slower than investors wanted, leading to a shift towards autoimmune disorders.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
2.35% Other Institutional Investors
97.65% Public Companies and
Individual Investors
F6T FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was €1.57 and its highest was €7.59 in the past 12 months.
What is Fate Therapeutics’s market cap?
Currently, no data Available
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is May 01, 2024 which is in 3 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Feb 26, 2024. The company reported -€0.422 earnings per share for the quarter, beating the consensus estimate of -€0.489 by €0.068.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -€0.45.
How many shares outstanding does Fate Therapeutics have?
Currently, no data Available
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -€0.422 in its last earnings report, beating expectations of -€0.489. Following the earnings report the stock price went up 5.969%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Among the largest hedge funds holding Fate Therapeutics’s share is Grosvenor Holdings, L.L.C.. It holds Fate Therapeutics’s shares valued at 4M.
---
Fate Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€6.78 (87.73% Upside)
€6.78 (87.73% Upside)
Blogger Sentiment
Bearish
DE:F6T Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.70%
12-Months-Change
Fundamentals
Return on Equity
-37.76%
Trailing 12-Months
Asset Growth
-28.25%
Trailing 12-Months
Company Description
Fate Therapeutics
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
---
F6T Earnings Call
Q4 2024
0:00 / 0:00
---
F6T Stock 12 Months Forecast
Average Price Target
€6.78
▲(87.73% Upside)
Technical Analysis
Fate Therapeutics
―
Crispr Therapeutics AG
―
Bluebird Bio
―
Meiragtx Holdings
―
Allogene Therapeutics
―
Best Analysts Covering F6T
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
-0.08%
assigned a buy rating 4 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -0.08% per trade.
---